SandRidge Energy, has priced its formerly declared private offering of $1 billion in aggregate principal amount of senior secured notes due 2020. The offering size was raised to $1.25 billion from $1.0 billion. The Notes will bear interest at a rate of 8.75% per annum and will be issued at par. The Notes will be secured on a second lien priority basis and guaranteed by each of the Company’s auxiliaries that guarantee the Company’s revolving credit facility. The issuance of the Notes and the effectiveness of the Company’s revised fully-committed $500 million borrowing base first-lien revolving credit facility, which are mutually conditioned on each other, are predictable to close on June 10, 2015, subject to customary closing conditions.
The Company intends to use a portion of the net proceeds from this offering to repay all borrowings under its existing revolving credit facility and for general corporate purposes.
SandRidge Energy, Inc., an oil and natural gas company, explores for and produces oil and natural gas properties primarily in the Mid-Continent region of the United States. The company operates through three segments: Exploration and Production, Drilling and Oil Field Services, and Midstream Services.
Shares of Merck & Co. Inc. (NYSE:MRK), inclined 0.40% to $59.70, during its last trading session.
Merck & Co., known as MSD outside the United States and Canada, declared that the company has presented a New Drug Application to the U.S. Food and Drug Administration (FDA) for grazoprevir/elbasvir (100mg/50mg), an investigational once-daily, single tablet combination therapy for the treatment of adult patients with chronic hepatitis C genotypes (GT) 1, 4 or 6 infection. Within 60 days of submission, the FDA will determine whether it will accept for review Merck’s application as filed. The company plans to submit additional license applications in the European Union and other markets by the end of 2015.
The FDA has formerly granted Breakthrough Therapy designation status for grazoprevir/elbasvir for the treatment of patients infected with chronic HCV GT1 with end stage renal disease on hemodialysis, and for patients infected with chronic HCV GT4. Breakthrough Therapy designation is intended to expedite the development and review of a candidate that is planned for use, alone or in combination, to treat a serious or life-threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically noteworthy endpoints.
The New Drug Application for grazoprevir/elbasvir (100mg/50mg) is based in part upon data from the pivotal C-EDGE clinical trials program, in addition to the C-SURFER and C-SALVAGE trials, evaluating grazoprevir/elbasvir (100mg/50mg), with or without ribavirin, in patients with chronic hepatitis C infection. Data from these trials were presented at The International Liver CongressTM 2015 in April 2015.
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.
At the end of Thursday’s trade, Shares of Staples, Inc. (NASDAQ:SPLS), gained 1.66% to $16.49.
Staples, declared the results for its first quarter ended May 2, 2015. Total company sales for the first quarter of 2015 were $5.3 billion, a decrease of seven percent contrast to the first quarter of 2014. On a GAAP basis, the company stated net income of $59 million, or $0.09 per diluted share, contrast to net income of $96 million, or $0.15 per diluted share, achieved in the first quarter of 2014. First quarter 2015 results on a GAAP basis comprise pre-tax charges of $45 million related to restructuring and related activities, $22 million of impairment primarily related to certain information technology assets, $15 million related to the acquisition of Office Depot, and a pre-tax gain of about $3 million related to the sale of assets.
Total company sales declined less than one percent during the first quarter, not taking into account the impact of store closures in North America during the past year and changes in foreign exchange rates. Not taking into account the impact of charges taken during the first quarter of 2015, the company stated non-GAAP net income of $109 million, or $0.17 per diluted share.
Staples, Inc., together with its auxiliaries, operates office products superstores. It operates through three segments: North American Stores & Online, North American Commercial, and International Operations. The company offers a range of office supplies, business technology products and services, facility and breakroom supplies, computers and mobility products, and office furniture under the Staples, Quill, and other proprietary brands.
Finally, Workday, Inc. (NYSE:WDAY), ended its last trade with -2.27% loss, and closed at $80.14.
Workday, declared that Aneel Bhusri, co-founder and CEO of Workday, will be a keynote speaker at the Bank of America Merrill Lynch 2015 Global Technology Conference in San Francisco, Calif. on Tuesday, June 2, 2015. The keynote is planned to start at 12:15 p.m. Pacific Time / 3:15 p.m. Eastern Time.
Workday, Inc. provides enterprise cloud applications for finance and human resources in the United States and internationally. It offers applications for customers to manage critical business functions that enable them to optimize their financial and human capital resources.
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
This article was originally published on WS News Publishers at the following link … Stocks to Track: SandRidge Energy, Inc. (NYSE:SD), Merck & Co. Inc. (NYSE:MRK), Staples, Inc. (NASDAQ:SPLS), Workday, Inc. (NYSE:WDAY)